Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just for clarity AI Metrics could offer sales and marketing rights to other parties BUT nobody else can distribute the software unless through IB and without IB receiving a royalty. DYOR
Expecting another big week here, plenty of news in the pipeline...
'One in three MRI scans use contrast to improve the diagnostic accuracy of the scan. In the US alone, that equates to approximately 10 million scans per year of which 40% are neuro scans. While the associated cost savings of contrast agent material alone is substantial, the potential impact to routine clinical practice is also significant. For instance, not having to inject contrast agents results in more efficient clinical workflows. Moreover, since the administration of contrast agent is not always performed properly and may result in lost scanner time or rescheduled scans, patient throughput and scanner utilisation may also increase. There are also costs associated with the power injectors themselves. Most importantly, a successful gad-free program will further reduce the potential risks associated with gadolinium retention in the body.'
Just the material cost of using Gad is circa $1.2 billion a year in the US alone & with the unknown health effects, associated costs etc it is a no brainer for clinics/hospitals. Patent applied for in 2018.
The previous placing was absolutely necessary & has enabled development at an accelerated rate that has taken us to where we are now with IB Neuro, LSN, IB Stroke, SC v.2 (imminent) on the market as well as Gad free, auto segmentation, IB Trax ,IB CAD & 'other' developments that have been alluded to but not in the public domain.
They don't need the cash so why do a placing? They know where the future of the company is going & remember contracts are now coming in so cashflow is not an issue.
'During this period, requests for trials of SC, as well as inquiries from international distributors, have been steadily received. Feedback from these trials has provided the opportunity for end users to use SC and identify fundamental workflow enhancements which are now being readily addressed and implemented by IQ-AI's development team. The team is now preparing to release version 2.0 of SC in early Q4 2020.'
https://www.share-talk.com/share-talk-bulletin-board-heroes-wednesday-4th-november-2020/#gs.kiery4
' A multi-baggers journey is filled with the corpses of highly intelligent articulate naysayers. Every investors strategy is different, so don’t waste a lot of time defending your positions to others. Do the work. Trust your work. Let company execution prove you right or wrong.'
Suggested research - Mayo clinic...
This is another great step forward for IQAI. Cancers, strokes & other illnesses are not waiting for Covid to be over they are happening & being treated now at a huge cost - with the additional burden of the virus the need for tech to streamline processes to aid & reduce the burden on clinicians, reduce costs & enhance patient outcomes is needed more now than ever. This is why we have seen the CMS ruling offering grants to medical centres adopting new tech to reduce costs, we have seen IB being taken up by Keck & as the interest was echoed by TB in the SC decision & states 'Interest in medical application in AI has intensified considerably as the year has progressed'
Plenty more news due over the coming weeks & as more pieces of the puzzle come together the interest should really build here & once news of contracts arrive then...
By the time a LOI is signed the terms of the deal would have been laid out & agreed so why pull out 2 months into the due diligence unless they had good reason to!? DS discusses SCs potential in an interview from last year where he mentioned a subscription model that could see $10,000 per clinic per month derived from the cost saving potential of the technology.
https://youtu.be/5X4Zz1V3KNU
The RNS states 'trials of SC, as well as inquiries from international distributors, have been steadily received.' which suggests they have already been in discussions with partners to implement a commercial route to market themselves with some success !? Each to their own opinion but there doesn't seem any logical reason to not sell unless this were true.
I would expect to hear news of partners / distribution deals to follow its release, so I am excited to see what they do with it.
If you look at the subscription model DS mentions for SC it makes the potential for products like IB stroke even more exciting - IB Stroke will offer a product to reduce vastly larger medical costs than SC & with that a much higher subscription. Its release is any day now. There are also updates on a few other company making products to come this quarter so we will not be short of RNS over the coming weeks..DYOR
Take your pick of the things that are going on here as the reason for the rise. The SC sale is just a small piece of the overall picture. IB stroke launch, further grant, further contracts, auto segmentation & Gad free projects - still other areas to be announced!? So much going on I would expect regular announcements to hit in October.
DS still in the picture as a consultant with a vested interest here but suspect Schmainda will continue to do interviews (he's getting better!) + the fundamentals will start to drive it from here on.
Start of Quarter 4 next week, big news to come..
I have not been able to find the old DS interview but I think it was rumoured to be 30M to 50M with existing products at that time.
Even if it has been misquoted, doesn't mean it is not achievable certainly if they have success with Gad free - this would be a very small fraction of the market. A couple more contracts and the market may catch on..
https://www.imagingbiometrics.com/wpib/wp-content/uploads/2020/09/IQ-AI-Strategy-Update-IB-Neuro-Standardized-Imaging-Protocol-for-Brain-Tumor-Patients.pdf
'Along with Keck Medical Center, other cancer centres are reaching out to IB with interest..'
This is the start.